Literature DB >> 28703214

Stop Alzheimer's before it starts.

Eric McDade1, Randall J Bateman2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28703214     DOI: 10.1038/547153a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  11 in total

1.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

Review 2.  Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.

Authors:  Maria C Carrillo; H Robert Brashear; Veronika Logovinsky; J Michael Ryan; Howard H Feldman; Eric R Siemers; Susan Abushakra; Dean M Hartley; Ronald C Petersen; Ara S Khachaturian; Reisa A Sperling
Journal:  Alzheimers Dement       Date:  2013-02-12       Impact factor: 21.566

3.  The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Authors:  Jeff Sevigny; Ping Chiao; Thierry Bussière; Paul H Weinreb; Leslie Williams; Marcel Maier; Robert Dunstan; Stephen Salloway; Tianle Chen; Yan Ling; John O'Gorman; Fang Qian; Mahin Arastu; Mingwei Li; Sowmya Chollate; Melanie S Brennan; Omar Quintero-Monzon; Robert H Scannevin; H Moore Arnold; Thomas Engber; Kenneth Rhodes; James Ferrero; Yaming Hang; Alvydas Mikulskis; Jan Grimm; Christoph Hock; Roger M Nitsch; Alfred Sandrock
Journal:  Nature       Date:  2016-09-01       Impact factor: 49.962

4.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

Authors:  Matthew E Kennedy; Andrew W Stamford; Xia Chen; Kathleen Cox; Jared N Cumming; Marissa F Dockendorf; Michael Egan; Larry Ereshefsky; Robert A Hodgson; Lynn A Hyde; Stanford Jhee; Huub J Kleijn; Reshma Kuvelkar; Wei Li; Britta A Mattson; Hong Mei; John Palcza; Jack D Scott; Michael Tanen; Matthew D Troyer; Jack L Tseng; Julie A Stone; Eric M Parker; Mark S Forman
Journal:  Sci Transl Med       Date:  2016-11-02       Impact factor: 17.956

5.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Authors:  Liang Wang; Tammie L Benzinger; Yi Su; Jon Christensen; Karl Friedrichsen; Patricia Aldea; Jonathan McConathy; Nigel J Cairns; Anne M Fagan; John C Morris; Beau M Ances
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302

Review 6.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

7.  Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology.

Authors:  Pritam Das; Christophe Verbeeck; Lisa Minter; Paramita Chakrabarty; Kevin Felsenstein; Thomas Kukar; Ghulam Maharvi; Abdul Fauq; Barbara A Osborne; Todd E Golde
Journal:  Mol Neurodegener       Date:  2012-08-14       Impact factor: 14.195

Review 8.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Authors:  Albert Wiegman; Samuel S Gidding; Gerald F Watts; M John Chapman; Henry N Ginsberg; Marina Cuchel; Leiv Ose; Maurizio Averna; Catherine Boileau; Jan Borén; Eric Bruckert; Alberico L Catapano; Joep C Defesche; Olivier S Descamps; Robert A Hegele; G Kees Hovingh; Steve E Humphries; Petri T Kovanen; Jan Albert Kuivenhoven; Luis Masana; Børge G Nordestgaard; Päivi Pajukanta; Klaus G Parhofer; Frederick J Raal; Kausik K Ray; Raul D Santos; Anton F H Stalenhoef; Elisabeth Steinhagen-Thiessen; Erik S Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen; Olov Wiklund
Journal:  Eur Heart J       Date:  2015-05-25       Impact factor: 29.983

Review 9.  A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

Authors:  Eric Karran; John Hardy
Journal:  Ann Neurol       Date:  2014-07-02       Impact factor: 10.422

10.  Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment.

Authors:  M Brendel; A Jaworska; J Herms; J Trambauer; C Rötzer; F-J Gildehaus; J Carlsen; P Cumming; J Bylund; T Luebbers; P Bartenstein; H Steiner; C Haass; K Baumann; A Rominger
Journal:  Mol Psychiatry       Date:  2015-06-09       Impact factor: 15.992

View more
  65 in total

1.  A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β-Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and H2O2-Induced Cytotoxicity in SH-SY5Y Cells.

Authors:  Chen Cheng; Nan Zheng; Deyang Sun; Weishuo Fang; Lingling Zheng; Weihong Song; Jian Huang
Journal:  Neurochem Res       Date:  2020-06-18       Impact factor: 3.996

2.  Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development.

Authors:  Sonia M Vallabh; Chloe K Nobuhara; Franc Llorens; Inga Zerr; Piero Parchi; Sabina Capellari; Eric Kuhn; Jacob Klickstein; Jiri G Safar; Flavia C Nery; Kathryn J Swoboda; Michael D Geschwind; Henrik Zetterberg; Steven E Arnold; Eric Vallabh Minikel; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-01       Impact factor: 11.205

Review 3.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 4.  Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

Authors:  Yuetiva Deming; Zeran Li; Bruno A Benitez; Carlos Cruchaga
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

5.  Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

Authors:  Adam M Staffaroni; Lynn Bajorek; Kaitlin B Casaletto; Yann Cobigo; Sheng-Yang M Goh; Amy Wolf; Hilary W Heuer; Fanny M Elahi; Peter A Ljubenkov; Reilly Dever; John Kornak; Brian Appleby; Jessica Bove; Yvette Bordelon; Patrick Brannelly; Danielle Brushaber; Christina Caso; Giovanni Coppola; Christina Dheel; Bradford C Dickerson; Susan Dickinson; Sophia Dominguez; Kimiko Domoto-Reilly; Kelly Faber; Jessica Ferrall; Julie A Fields; Ann Fishman; Jamie Fong; Tatiana Foroud; Leah K Forsberg; Ralitza Gavrilova; Debra Gearhart; Behnaz Ghazanfari; Nupur Ghoshal; Jill Goldman; Jonathan Graff-Radford; Neill Graff-Radford; Ian Grant; Murray Grossman; Dana Haley; Ging-Yuek Hsiung; Edward D Huey; David J Irwin; David T Jones; Lynne Jones; Kejal Kantarci; Anna Karydas; Daniel I Kaufer; Diana R Kerwin; David S Knopman; Ruth Kraft; Walter K Kremers; Walter A Kukull; Irene Litvan; Diane Lucente; Codrin Lungu; Ian R Mackenzie; Miranda Maldonado; Masood Manoochehri; Scott M McGinnis; Emily McKinley; Mario F Mendez; Bruce L Miller; Namita Multani; Chiadi Onyike; Jaya Padmanabhan; Alex Pantelyat; Rodney Pearlman; Len Petrucelli; Madeline Potter; Rosa Rademakers; Eliana Marisa Ramos; Katherine P Rankin; Katya Rascovsky; Erik D Roberson; Emily Rogalski; Pheth Sengdy; Leslie M Shaw; Jeremy Syrjanen; M Carmela Tartaglia; Nadine Tatton; Joanne Taylor; Arthur Toga; John Q Trojanowski; Sandra Weintraub; Ping Wang; Bonnie Wong; Zbigniew Wszolek; Adam L Boxer; Brad F Boeve; Joel H Kramer; Howard J Rosen
Journal:  Alzheimers Dement       Date:  2019-05-11       Impact factor: 21.566

6.  Dynamic network connectivity predicts subjective cognitive decline: the Sino-Longitudinal Cognitive impairment and dementia study.

Authors:  Guozhao Dong; Liu Yang; Chiang-Shan R Li; Xiaoni Wang; Yihe Zhang; Wenying Du; Ying Han; Xiaoying Tang
Journal:  Brain Imaging Behav       Date:  2020-12       Impact factor: 3.978

7.  Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.

Authors:  Ron Brookmeyer; Nada Abdalla
Journal:  Clin Trials       Date:  2019-04       Impact factor: 2.486

8.  Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease.

Authors:  Panagiotis Alexopoulos; Jennifer Roesler; Lukas Werle; Nathalie Thierjung; Iliana Lentzari; Marion Ortner; Timo Grimmer; Nikolaos Laskaris; Antonios Politis; Philippos Gourzis; Alexander Kurz; Robert Perneczky
Journal:  J Neural Transm (Vienna)       Date:  2017-11-15       Impact factor: 3.575

Review 9.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

10.  Impaired Hippocampal-Cortical Interactions during Sleep in a Mouse Model of Alzheimer's Disease.

Authors:  Sarah D Benthem; Ivan Skelin; Shawn C Moseley; Alina C Stimmell; Jessica R Dixon; Andreza S Melilli; Leonardo Molina; Bruce L McNaughton; Aaron A Wilber
Journal:  Curr Biol       Date:  2020-05-28       Impact factor: 10.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.